Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Completed · Phase 1 · Has a placebo group

Conditions studied: Epilepsy

In brief

The primary objective of the study is to evaluate the neurocognitive effects of brivaracetam

Key facts

Study ID

NCT00736931

Run by

UCB Pharma

People needed

20

Starts

2008-07-01

Expected to finish

2008-10-01

Last updated by the study team

2012-05-28

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female volunteer aged 18 to 50 years inclusive
• Body Mass Index (BMI) between 18.0 and 30.0 kg/m² inclusive
• Good physical and mental health status
• Blood pressure and heart rate within normal range
• Electrocardiogram and laboratory tests without clinically significant abnormality

You may not qualify if…

• IQ ≤ 80 as determined by Test of non-verbal intelligence
• Center for Epidemiological Studies Depression (CES-D Scale ≥16,
• Known allergy/intolerance to pyrrolidinone derivatives
• Abnormalities on EEG recordings
• Pregnant, lactating women
• History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, psychiatric disorders
• Use of any hepatic enzyme-inducing drug

Where it is running

• Study site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.